After demonstrating that miR-375 contributes to PCa progression through phosphatase nonreceptor type 4 (PTPN4)/STAT3 signaling and could be a novel therapeutic target for PCa, we next loaded hucMSC-derived exosomes with miR-375 antisense PMOs (e-375i) by an in vitro engineering method and then evaluated the therapeutic and drug resensitizing effects of these miR-375 targeting complexes in vitro and in vivo. Here, PTPN4 is linked to posterior cortical atrophy.